Navigation Links
OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Date:12/4/2008

BOTHELL, WA, and VANCOUVER, Dec. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc (NASDAQ: OGXI) will participate on the 'Waging a Battle Against Cancer' panel at the RBC Capital Markets 2008 Healthcare Conference on Thursday, December 11 at 8:00 am ET at the Westin Times Square Hotel in New York. During the panel discussion, OncoGenex' President and Chief Executive Officer, Scott Cormack, will provide a brief overview of the company's oncology drug pipeline and its approach for addressing cancer treatment resistance.

A live webcast of the panel will be available on the Events section of the Investor Relations page of the company Web site at www.oncogenex.com. A replay of the webcast will be available for 30 days following the event.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 and SN2310 are in Phase 1 clinical development; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at www.oncogenex.com.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014 About ... testing, is performed outside a clinical laboratory. It ... in administrating appropriate treatments and medication. POCT is ... prevalence of lifestyle diseases such as diabetes, heart ... user-friendly. POCT devices are standardized to minimize errors ...
(Date:9/18/2014)... Station, Texas (PRWEB) September 18, 2014 ... System Chancellor John Sharp, Texas A&M Health Science ... the U.S. Department of Health and Human Services ... today dedicated a national pandemic influenza vaccine manufacturing ... serve as an anchor for the Texas A&M ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ ... report to their offering. The ... a CAGR of 22.7% from 2014 to 2019. Factors ... treatment, growing adoption of companion diagnostics by the pharmaceutical ...
(Date:9/18/2014)... SEATTLE , Sept. 18, 2014 /PRNewswire/ - Oncothyreon ... pricing of previously announced concurrent but separate underwritten offerings ... price to the public of $2.00 per share, for ... of its Series A Convertible Preferred Stock at a ... expected gross proceeds of $20 million. Each share of ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... Bavituximab, Currently in Phase II Cancer Trials in Combination with ... Chemotherapy -, ... ... Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing monoclonal antibodies for ...
... design offers enhanced convenience, ease-of-use, and helps optimize ... ... March 3 Metrex Research Corporation is,pleased to announce the newest ... unique patented design offers a new,easy-open/easy-close pull tab with slim, flexible ...
... Disposables, Services and Accessories Revenue Up 102% ... ST. LOUIS, March 3 Stereotaxis, Inc. (Nasdaq:,STXS) ... full year,ended December 31, 2007., For the full ... $27.2 million in 2006. Sales of the Niobe(TM) system ...
Cached Biology Technology:Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 2Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 3Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 4Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity 5CaviWipes(R): Taking Surface Disinfection to a New Level 2Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 2Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 3Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 4Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 5Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 6Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 7Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 8Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 9Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 10
(Date:9/18/2014)... small, icy moon of Uranus, is one of the ... system. Despite its relatively small size, Miranda appears to ... in the formation of at least three remarkable and ... , These coronae are visible in Miranda,s southern hemisphere, ... Arden corona, the largest, has ridges and troughs with ...
(Date:9/18/2014)... can operate inside the bore of an MRI scanner ... research partnership program at Brigham and Women,s Hospital in ... in conjunction with real-time MRI images, can make prostate ... discomforting for the patient. The novel system also has ... precision. , Developed by a team of robotics engineers ...
(Date:9/18/2014)... the International Space Station ever starts a "frequent flyers" ... status. Recently the orbiting laboratory has hosted increasing numbers ... returned from the space station in April, and another ... third experiment is planned to launch in December. , ... around the world-- and in space. Model organisms can ...
Breaking Biology News(10 mins):Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4
... For the first time, a study by researchers at Columbia ... post-traumatic stress disorder (PTSD) among adults. The study of male ... the association between asthma and PTSD is not primarily explained ... twin pairs, who had lived together in childhood, and who ...
... N.Y. Single-molecule biologythe revolutionary field that deals ... Tremendous technical advances have made it possible to ... images as they twist, twirl, wobble, and unfold. ... book that was just released by Cold Spring Harbor ...
... MADISON - When University of Wisconsin-Madison researchers succeeded in ... they also began to redefine the political and ethical ... Alta Charo, a UW-Madison professor of law and bioethics, ... the social dimensions of the ongoing controversy over embryonic ...
Cached Biology News:Asthma link to post-traumatic stress disorder, says Mailman School of Public Health study 2New book presents methods to poke and prod individual molecules 2Reprogramming the debate: stem-cell finding alters ethical controversy 2Reprogramming the debate: stem-cell finding alters ethical controversy 3
... Immunogen: Synthetic peptide derived from an ... mTOR (Mammalian target of rapamycin FRAP RAFT1 ... mTOR protein. On Western blots it ... Reactivity: Human (positive control: HEK293 cell ...
MW5...
... Intended to qualitatively ... in formalin-fixed, paraffin-embedded (FFPE) ... spreads, and cell preparations, ... Hybridization (CISH). Fluorescent In ...
From micro to giga sizes, from single prep to high-throughput, Invitrogen's range of plasmid purification kits offers superior performance to match the demands of your downstream application....
Biology Products: